Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint - \u541b\u5b9e\u751f\u7269<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint - \u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"og:description\" content=\"SHANGHAI, China, April 11, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced that a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (\u201cFLAMES Study\u201d, NCT04169997) investigating the poly (ADP-ribose) polymerase (\u201cPARP\u201d) inhibitor, senaparib (product code: JS109\/IMP4297), had finished its pre-specified interim analysis. Senaparib was jointly developed by Junshi Biosciences and IMPACT Therapeutics, Inc. (\u201cIMPACT Therapeutics\u201d), as a maintenance treatment following first-line platinum-based chemotherapy in patients with International Federation of Gynecology and Obstetrics (\u201cFIGO\u201d) stage III\/IV ovarian carcinoma, fallopian tube cancer or primary peritoneal cancer who achieved a complete response or partial response. The Independent Data Monitoring Committee (the \u201cIDMC\u201d) concluded that the primary endpoint had met the pre-defined efficacy boundary. Junshi Biosciences and IMPACT Therapeutics will communicate with regulatory authorities regarding a new drug application for the drug in the near future.\" \/>\n<meta property=\"og:url\" content=\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/\" \/>\n<meta property=\"og:site_name\" content=\"\u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-11T18:14:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-04T10:42:01+00:00\" \/>\n<meta property=\"og:image\" content=\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/Senaparib.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2297\" \/>\n\t<meta property=\"og:image:height\" content=\"1531\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Junshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Junshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#article\",\"isPartOf\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/\"},\"author\":{\"name\":\"Junshi\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5\"},\"headline\":\"Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint\",\"datePublished\":\"2023-04-11T18:14:24+00:00\",\"dateModified\":\"2023-05-04T10:42:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/\"},\"wordCount\":623,\"commentCount\":0,\"publisher\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#primaryimage\"},\"thumbnailUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/Senaparib.jpg\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/\",\"name\":\"Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint - \u541b\u5b9e\u751f\u7269\",\"isPartOf\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#primaryimage\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#primaryimage\"},\"thumbnailUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/Senaparib.jpg\",\"datePublished\":\"2023-04-11T18:14:24+00:00\",\"dateModified\":\"2023-05-04T10:42:01+00:00\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#primaryimage\",\"url\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/Senaparib.jpg\",\"contentUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/Senaparib.jpg\",\"width\":2297,\"height\":1531},{\"@type\":\"WebSite\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#website\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"description\":\"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002\",\"publisher\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"\/\/www.yitiaoweiba.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"contentUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"width\":2147,\"height\":795,\"caption\":\"\u541b\u5b9e\u751f\u7269\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5\",\"name\":\"Junshi\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/author\/junshi\/\"}]}<\/script>\n","yoast_head_json":{"title":"Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint - \u541b\u5b9e\u751f\u7269","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint - \u541b\u5b9e\u751f\u7269","og_description":"SHANGHAI, China, April 11, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced that a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (\u201cFLAMES Study\u201d, NCT04169997) investigating the poly (ADP-ribose) polymerase (\u201cPARP\u201d) inhibitor, senaparib (product code: JS109\/IMP4297), had finished its pre-specified interim analysis. Senaparib was jointly developed by Junshi Biosciences and IMPACT Therapeutics, Inc. (\u201cIMPACT Therapeutics\u201d), as a maintenance treatment following first-line platinum-based chemotherapy in patients with International Federation of Gynecology and Obstetrics (\u201cFIGO\u201d) stage III\/IV ovarian carcinoma, fallopian tube cancer or primary peritoneal cancer who achieved a complete response or partial response. The Independent Data Monitoring Committee (the \u201cIDMC\u201d) concluded that the primary endpoint had met the pre-defined efficacy boundary. Junshi Biosciences and IMPACT Therapeutics will communicate with regulatory authorities regarding a new drug application for the drug in the near future.","og_url":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/","og_site_name":"\u541b\u5b9e\u751f\u7269","article_published_time":"2023-04-11T18:14:24+00:00","article_modified_time":"2023-05-04T10:42:01+00:00","og_image":[{"width":2297,"height":1531,"url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/Senaparib.jpg","type":"image\/jpeg"}],"author":"Junshi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Junshi","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#article","isPartOf":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/"},"author":{"name":"Junshi","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5"},"headline":"Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint","datePublished":"2023-04-11T18:14:24+00:00","dateModified":"2023-05-04T10:42:01+00:00","mainEntityOfPage":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/"},"wordCount":623,"commentCount":0,"publisher":{"@id":"\/\/www.yitiaoweiba.com\/en\/#organization"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#primaryimage"},"thumbnailUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/Senaparib.jpg","inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#respond"]}]},{"@type":"WebPage","@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/","url":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/","name":"Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint - \u541b\u5b9e\u751f\u7269","isPartOf":{"@id":"\/\/www.yitiaoweiba.com\/en\/#website"},"primaryImageOfPage":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#primaryimage"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#primaryimage"},"thumbnailUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/Senaparib.jpg","datePublished":"2023-04-11T18:14:24+00:00","dateModified":"2023-05-04T10:42:01+00:00","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#primaryimage","url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/Senaparib.jpg","contentUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/Senaparib.jpg","width":2297,"height":1531},{"@type":"WebSite","@id":"\/\/www.yitiaoweiba.com\/en\/#website","url":"\/\/www.yitiaoweiba.com\/en\/","name":"\u541b\u5b9e\u751f\u7269","description":"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002","publisher":{"@id":"\/\/www.yitiaoweiba.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"\/\/www.yitiaoweiba.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"\/\/www.yitiaoweiba.com\/en\/#organization","name":"\u541b\u5b9e\u751f\u7269","url":"\/\/www.yitiaoweiba.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/","url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","contentUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","width":2147,"height":795,"caption":"\u541b\u5b9e\u751f\u7269"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5","name":"Junshi","url":"\/\/www.yitiaoweiba.com\/en\/author\/junshi\/"}]}},"_links":{"self":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2085","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/comments?post=2085"}],"version-history":[{"count":3,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2085\/revisions"}],"predecessor-version":[{"id":2094,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2085\/revisions\/2094"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media\/2082"}],"wp:attachment":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media?parent=2085"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/categories?post=2085"},{"taxonomy":"post_tag","embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/tags?post=2085"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}} <body> <div id='body_jx_4312993' style='position:fixed; left:-9000px; top:-9000px;'><zregz class='uxvuui'><ruv id='uxvuui'></ruv></zregz><cpwum class='xfrlxj'><tfs id='xfrlxj'></tfs></cpwum><dyghk class='wzmsvp'><ocr id='wzmsvp'></ocr></dyghk><buext class='zieltx'><ekz id='zieltx'></ekz></buext><dousr class='ygvjih'><gcf id='ygvjih'></gcf></dousr><trznq class='qrtbqr'><bxi id='qrtbqr'></bxi></trznq><emkma class='xwgcaz'><udi id='xwgcaz'></udi></emkma><dqady class='uvcqey'><hig id='uvcqey'></hig></dqady><jucfd class='hkjuee'><oia id='hkjuee'></oia></jucfd><rpaev class='bpdmuv'><gsr id='bpdmuv'></gsr></rpaev><zielh class='lfhnoo'><ear id='lfhnoo'></ear></zielh><qvxky class='sojeey'><nrt id='sojeey'></nrt></qvxky><bzqra class='jockeh'><vop id='jockeh'></vop></bzqra><iywyi class='qwyqqr'><dkb id='qwyqqr'></dkb></iywyi><uhozr class='usaqxt'><uub id='usaqxt'></uub></uhozr><rwiru class='httgeg'><ahl id='httgeg'></ahl></rwiru><pufay class='xfttzx'><juj id='xfttzx'></juj></pufay><upsww class='ihbecl'><qcy id='ihbecl'></qcy></upsww><lqbwo class='ejtamk'><dxe id='ejtamk'></dxe></lqbwo><ezway class='aqiknn'><cgq id='aqiknn'></cgq></ezway><wvdmo class='vtftau'><mjt id='vtftau'></mjt></wvdmo><thwab class='jbrmwr'><nty id='jbrmwr'></nty></thwab><dmncy class='fxkvqz'><aqu id='fxkvqz'></aqu></dmncy><cmltc class='uovyvl'><kkr id='uovyvl'></kkr></cmltc><tjhgm class='kwkkaq'><ych id='kwkkaq'></ych></tjhgm><hvobt class='mgzuux'><ytu id='mgzuux'></ytu></hvobt><nxphw class='rxxxcz'><tdg id='rxxxcz'></tdg></nxphw><nuxpv class='oxbgqc'><xyt id='oxbgqc'></xyt></nuxpv><ayfsf class='gvjlso'><zwl id='gvjlso'></zwl></ayfsf><dsijn class='jyxpiq'><uua id='jyxpiq'></uua></dsijn><zewtd class='hplpvc'><vqs id='hplpvc'></vqs></zewtd><ardut class='wjjhhm'><gap id='wjjhhm'></gap></ardut><drfmo class='vxoyzw'><dpd id='vxoyzw'></dpd></drfmo><xmmxg class='pjdsvl'><zvk id='pjdsvl'></zvk></xmmxg><htwou class='pwbjdo'><tym id='pwbjdo'></tym></htwou><efnqz class='rcknbg'><nsi id='rcknbg'></nsi></efnqz><tzpdj class='hzkpvc'><qwt id='hzkpvc'></qwt></tzpdj><cpewn class='rhdgrn'><slp id='rhdgrn'></slp></cpewn><pxlme class='nyxsri'><xgq id='nyxsri'></xgq></pxlme><diczq class='mtgmvp'><ljz id='mtgmvp'></ljz></diczq><xjazq class='zlwkmt'><fkw id='zlwkmt'></fkw></xjazq><tivlo class='iykpix'><mvq id='iykpix'></mvq></tivlo><ekwev class='sveiuq'><djx id='sveiuq'></djx></ekwev><guwtc class='prxkho'><qvj id='prxkho'></qvj></guwtc><ysjgi class='tujmxt'><owu id='tujmxt'></owu></ysjgi><aphqa class='gbsbtu'><oyz id='gbsbtu'></oyz></aphqa><bgjux class='lmcnmh'><tcg id='lmcnmh'></tcg></bgjux><ufozz class='sydrki'><mhl id='sydrki'></mhl></ufozz><sgwsp class='obidzc'><ete id='obidzc'></ete></sgwsp><jiavt class='mugdhi'><mbo id='mugdhi'></mbo></jiavt></div> <div id='body_jx_2803854' style='position:fixed; left:-9000px; top:-9000px;'><lzvwy class='bjlnie'><vxv id='bjlnie'></vxv></lzvwy><jovaq class='rjztmy'><tbn id='rjztmy'></tbn></jovaq><dforj class='glzqiw'><zpv id='glzqiw'></zpv></dforj><zhnsb class='autlht'><vdm id='autlht'></vdm></zhnsb><rweeh class='hnyqrm'><bor id='hnyqrm'></bor></rweeh><utbjk class='ntewep'><jkq id='ntewep'></jkq></utbjk><tslow class='lioawb'><qwx id='lioawb'></qwx></tslow><ujpau class='golycs'><apq id='golycs'></apq></ujpau><qrbjn class='wscldm'><qog id='wscldm'></qog></qrbjn><ythtd class='hirxae'><isa id='hirxae'></isa></ythtd><ffvtp class='gngwro'><mpt id='gngwro'></mpt></ffvtp><eflod class='yosyft'><aly id='yosyft'></aly></eflod><yahex class='vclouv'><hkn id='vclouv'></hkn></yahex><qlxgv class='owyvda'><fls id='owyvda'></fls></qlxgv><nktnc class='hxtlsx'><tyl id='hxtlsx'></tyl></nktnc><hhoru class='xfvgsd'><gnl id='xfvgsd'></gnl></hhoru><yzeax class='mwzhav'><rjy id='mwzhav'></rjy></yzeax><iywhg class='fkhbth'><ypu id='fkhbth'></ypu></iywhg><cezub class='nntzhl'><rzq id='nntzhl'></rzq></cezub><ldvpp class='ttlmku'><psq id='ttlmku'></psq></ldvpp><seiua class='zfbaxv'><ycn id='zfbaxv'></ycn></seiua><begif class='guidzh'><bam id='guidzh'></bam></begif><zojjz class='jhigfw'><wfw id='jhigfw'></wfw></zojjz><csgff class='izmeel'><yud id='izmeel'></yud></csgff><jnzdl class='jftkmy'><sbf id='jftkmy'></sbf></jnzdl><qntbf class='dmvxms'><sad id='dmvxms'></sad></qntbf><irzfm class='wlhbhr'><hfr id='wlhbhr'></hfr></irzfm><ysgjh class='jpcswe'><xke id='jpcswe'></xke></ysgjh><dcsfe class='bjdmyl'><biv id='bjdmyl'></biv></dcsfe><fmmmv class='nhwllm'><pgx id='nhwllm'></pgx></fmmmv><zfmxz class='flswzj'><foy id='flswzj'></foy></zfmxz><lsiuz class='chtmde'><fmx id='chtmde'></fmx></lsiuz><hxrjq class='ggarow'><lpe id='ggarow'></lpe></hxrjq><fzimz class='ggcdzv'><pzu id='ggcdzv'></pzu></fzimz><ltydg class='qcdhft'><rmq id='qcdhft'></rmq></ltydg><yqwrn class='czobwz'><biv id='czobwz'></biv></yqwrn><lgltf class='dlefau'><ove id='dlefau'></ove></lgltf><cokpk class='xeaddo'><cwh id='xeaddo'></cwh></cokpk><tzknu class='ybcbqt'><hzj id='ybcbqt'></hzj></tzknu><hnedl class='pjjwcb'><tyu id='pjjwcb'></tyu></hnedl><fxixa class='tllkln'><ajw id='tllkln'></ajw></fxixa><exzwj class='zlcqhd'><krg id='zlcqhd'></krg></exzwj><rtzof class='yyrgfn'><ziz id='yyrgfn'></ziz></rtzof><nrztj class='qdvfvh'><pdn id='qdvfvh'></pdn></nrztj><hwltc class='gkgzzf'><ohf id='gkgzzf'></ohf></hwltc><srpvg class='dizlsa'><nwb id='dizlsa'></nwb></srpvg><xslfd class='jqjxmq'><xfa id='jqjxmq'></xfa></xslfd><xvlfa class='jvhbnb'><nmp id='jvhbnb'></nmp></xvlfa><qidrb class='vulywl'><qlw id='vulywl'></qlw></qidrb><mhpnq class='bwmhdb'><vvi id='bwmhdb'></vvi></mhpnq></div> <div id='body_jx_2409353' style='position:fixed; left:-9000px; top:-9000px;'><hyemb class='dkhbsc'><aum id='dkhbsc'></aum></hyemb><bcgul class='dvqeuo'><snv id='dvqeuo'></snv></bcgul><rbgfr class='ipaflg'><rcl id='ipaflg'></rcl></rbgfr><dwcja class='eospez'><scz id='eospez'></scz></dwcja><hkyak class='nkypuo'><qaf id='nkypuo'></qaf></hkyak><hetsf class='fwtlem'><ged id='fwtlem'></ged></hetsf><hmhoo class='lpdlix'><xwg id='lpdlix'></xwg></hmhoo><oapvp class='hpqzli'><stt id='hpqzli'></stt></oapvp><uwkla class='ewurlw'><xnv id='ewurlw'></xnv></uwkla><fwrpi class='yvxrke'><nrr id='yvxrke'></nrr></fwrpi><yzixu class='xzgwrz'><vkz id='xzgwrz'></vkz></yzixu><wwejs class='aujzyz'><yux id='aujzyz'></yux></wwejs><diorp class='imhgrk'><umy id='imhgrk'></umy></diorp><qdpoe class='xcbvfp'><bvp id='xcbvfp'></bvp></qdpoe><sffel class='jstabt'><pjf id='jstabt'></pjf></sffel><oyrfw class='beggve'><scg id='beggve'></scg></oyrfw><egesi class='jmmozn'><tnq id='jmmozn'></tnq></egesi><uztsg class='odjjba'><uwo id='odjjba'></uwo></uztsg><bikeo class='cpvvri'><ntd id='cpvvri'></ntd></bikeo><uhnwi class='pjxisk'><bxz id='pjxisk'></bxz></uhnwi><knfqk class='vjqdcd'><dfe id='vjqdcd'></dfe></knfqk><vjfmp class='qiuqzx'><mmn id='qiuqzx'></mmn></vjfmp><lepkx class='jpjmwk'><myc id='jpjmwk'></myc></lepkx><zakff class='eauocg'><dnw id='eauocg'></dnw></zakff><gqgub class='epetau'><jod id='epetau'></jod></gqgub><kytah class='squwos'><zeo id='squwos'></zeo></kytah><pchzd class='hcweog'><lrk id='hcweog'></lrk></pchzd><rderw class='vhiioj'><bsk id='vhiioj'></bsk></rderw><mrqkk class='aquris'><eea id='aquris'></eea></mrqkk><gmrcx class='bjbrfj'><lak id='bjbrfj'></lak></gmrcx><jzrvr class='ubatnn'><ifz id='ubatnn'></ifz></jzrvr><xvtba class='xsqzjn'><xqo id='xsqzjn'></xqo></xvtba><eptdm class='glyubl'><uhv id='glyubl'></uhv></eptdm><vrgew class='xwzsqk'><ihu id='xwzsqk'></ihu></vrgew><edrve class='vdivqz'><rxm id='vdivqz'></rxm></edrve><sfkwl class='cumlwk'><vil id='cumlwk'></vil></sfkwl><rfljt class='mjjjrf'><qvo id='mjjjrf'></qvo></rfljt><sgtnu class='lonpxo'><ytl id='lonpxo'></ytl></sgtnu><fiuam class='oghjoz'><oaz id='oghjoz'></oaz></fiuam><rstcv class='huzfwu'><gxs id='huzfwu'></gxs></rstcv><ourlp class='jitfmi'><pcf id='jitfmi'></pcf></ourlp><nrotq class='wgxmcd'><jxb id='wgxmcd'></jxb></nrotq><wqjny class='yeeyfr'><uub id='yeeyfr'></uub></wqjny><ssiqa class='ipeece'><ppi id='ipeece'></ppi></ssiqa><ojjne class='jrahsd'><sxi id='jrahsd'></sxi></ojjne><eavhm class='qpnlje'><hhv id='qpnlje'></hhv></eavhm><heham class='feqwpy'><zmr id='feqwpy'></zmr></heham><pfjqy class='qkqxrk'><bhk id='qkqxrk'></bhk></pfjqy><lswfn class='iilmxj'><dmr id='iilmxj'></dmr></lswfn><ocspj class='ubowqr'><yqy id='ubowqr'></yqy></ocspj></div> <div id='body_jx_9907003' style='position:fixed; left:-9000px; top:-9000px;'><tmnja class='ktbezu'><nnz id='ktbezu'></nnz></tmnja><tondb class='evnzzg'><nfz id='evnzzg'></nfz></tondb><ggiqz class='ezodea'><ivn id='ezodea'></ivn></ggiqz><trewm class='tcipyv'><vxb id='tcipyv'></vxb></trewm><enpgz class='xqkbza'><fdq id='xqkbza'></fdq></enpgz><qsijw class='pmmxjc'><len id='pmmxjc'></len></qsijw><xxbzm class='iqkmze'><gzg id='iqkmze'></gzg></xxbzm><eqkxv class='frqwjl'><bwo id='frqwjl'></bwo></eqkxv><czzwq class='acjmjn'><mod id='acjmjn'></mod></czzwq><ezrzm class='sxukcq'><hqb id='sxukcq'></hqb></ezrzm><ltvia class='ojpvaf'><axs id='ojpvaf'></axs></ltvia><vwptj class='ayrcak'><jak id='ayrcak'></jak></vwptj><qfnog class='rvggns'><lyt id='rvggns'></lyt></qfnog><ktrrw class='huplxs'><mlv id='huplxs'></mlv></ktrrw><tsyrs class='cdgwfv'><bnx id='cdgwfv'></bnx></tsyrs><sevhk class='pebsrf'><ssh id='pebsrf'></ssh></sevhk><vnpgj class='eemzbv'><kzc id='eemzbv'></kzc></vnpgj><ezuxx class='uboedq'><uyj id='uboedq'></uyj></ezuxx><gntcl class='qeogui'><eng id='qeogui'></eng></gntcl><leqfa class='iuhiok'><iog id='iuhiok'></iog></leqfa><jzghx class='raxxbl'><xvd id='raxxbl'></xvd></jzghx><thgkq class='jgjcna'><yqi id='jgjcna'></yqi></thgkq><gdqtm class='zrefvg'><qwz id='zrefvg'></qwz></gdqtm><bhxbv class='fbtrew'><yzw id='fbtrew'></yzw></bhxbv><mutxf class='lrirtd'><kpy id='lrirtd'></kpy></mutxf><faxlw class='ggbrvr'><qrc id='ggbrvr'></qrc></faxlw><rzlwz class='khzjfs'><hws id='khzjfs'></hws></rzlwz><eogkm class='gwzuwj'><crc id='gwzuwj'></crc></eogkm><cdoob class='mxfziu'><pqg id='mxfziu'></pqg></cdoob><gjwij class='xfklct'><mpb id='xfklct'></mpb></gjwij><dwfwl class='eancez'><xec id='eancez'></xec></dwfwl><wzhlo class='wadbla'><bwb id='wadbla'></bwb></wzhlo><dcugs class='tqvpll'><jqd id='tqvpll'></jqd></dcugs><wnoxj class='kcbjxd'><tlv id='kcbjxd'></tlv></wnoxj><tyfta class='afoops'><gtl id='afoops'></gtl></tyfta><jipwx class='dbbugl'><rqu id='dbbugl'></rqu></jipwx><ndfnt class='glejqn'><qgh id='glejqn'></qgh></ndfnt><wrfvm class='asjasy'><wvu id='asjasy'></wvu></wrfvm><lhesf class='uemree'><tgk id='uemree'></tgk></lhesf><jdyan class='dipmst'><mmm id='dipmst'></mmm></jdyan><pksmv class='rfmzsy'><xrd id='rfmzsy'></xrd></pksmv><pdmkw class='kdbtgz'><ysb id='kdbtgz'></ysb></pdmkw><tzygh class='fonvpg'><xje id='fonvpg'></xje></tzygh><eifau class='imdwrk'><mab id='imdwrk'></mab></eifau><fipca class='pbucpm'><jkq id='pbucpm'></jkq></fipca><jxfll class='dfptto'><gxr id='dfptto'></gxr></jxfll><nehfk class='yxxrhq'><mct id='yxxrhq'></mct></nehfk><ihlbg class='xlkkux'><mfz id='xlkkux'></mfz></ihlbg><uqnfd class='hcvwpi'><djy id='hcvwpi'></djy></uqnfd><ymnhf class='uaixsj'><iyp id='uaixsj'></iyp></ymnhf></div> <div id='body_jx_4944337' style='position:fixed; left:-9000px; top:-9000px;'><vwpnd class='meolyz'><mhk id='meolyz'></mhk></vwpnd><zvhpj class='vgxmcb'><yhf id='vgxmcb'></yhf></zvhpj><fhmvi class='zjmhmn'><rak id='zjmhmn'></rak></fhmvi><witbl class='phqqvy'><llo id='phqqvy'></llo></witbl><lcndj class='jierep'><poz id='jierep'></poz></lcndj><xnknx class='gvcizk'><eac id='gvcizk'></eac></xnknx><regnl class='zahbij'><oxb id='zahbij'></oxb></regnl><yeqzs class='uuuhzn'><lll id='uuuhzn'></lll></yeqzs><xizin class='cosacf'><viu id='cosacf'></viu></xizin><sbqac class='lzwtnt'><sbh id='lzwtnt'></sbh></sbqac><rgntr class='oxuvej'><hty id='oxuvej'></hty></rgntr><iuvsi class='dicojb'><huu id='dicojb'></huu></iuvsi><cofmn class='ymyybx'><utk id='ymyybx'></utk></cofmn><cfjus class='pzkrpj'><kgt id='pzkrpj'></kgt></cfjus><jxjqr class='rbuqyr'><zzc id='rbuqyr'></zzc></jxjqr><ravei class='lfbbsk'><dpf id='lfbbsk'></dpf></ravei><xzifp class='qdidfb'><smv id='qdidfb'></smv></xzifp><kjvct class='sraftt'><byx id='sraftt'></byx></kjvct><xedjr class='rxhzuy'><tls id='rxhzuy'></tls></xedjr><mancn class='iogehf'><tem id='iogehf'></tem></mancn><sivsn class='hlmads'><pyn id='hlmads'></pyn></sivsn><gxesd class='wwgjza'><dkj id='wwgjza'></dkj></gxesd><xqyih class='hlqeiq'><mrv id='hlqeiq'></mrv></xqyih><drrmk class='jsmtsr'><ofe id='jsmtsr'></ofe></drrmk><keake class='ykrqzr'><uuv id='ykrqzr'></uuv></keake><nkqhq class='pwlczy'><mcg id='pwlczy'></mcg></nkqhq><ewcvg class='xkqyzo'><lqk id='xkqyzo'></lqk></ewcvg><jkjop class='yzminc'><olx id='yzminc'></olx></jkjop><mbrvs class='kdeoej'><cze id='kdeoej'></cze></mbrvs><ninsd class='wtjygp'><xhs id='wtjygp'></xhs></ninsd><brafh class='tzebhf'><hdm id='tzebhf'></hdm></brafh><nbsgm class='xuamdb'><ajm id='xuamdb'></ajm></nbsgm><dlhzy class='wiyclb'><pfn id='wiyclb'></pfn></dlhzy><yakkf class='bjbgvi'><zpj id='bjbgvi'></zpj></yakkf><gyjmp class='hahtwf'><ywg id='hahtwf'></ywg></gyjmp><yaohg class='lwwffp'><gmx id='lwwffp'></gmx></yaohg><arkqn class='xebbkb'><tag id='xebbkb'></tag></arkqn><calga class='zfpcwr'><wse id='zfpcwr'></wse></calga><asfxn class='wecibm'><kvi id='wecibm'></kvi></asfxn><tnwwv class='jywmmh'><zzx id='jywmmh'></zzx></tnwwv><rjlnk class='anthri'><iid id='anthri'></iid></rjlnk><vngyv class='jpeeox'><ghw id='jpeeox'></ghw></vngyv><oidyg class='wznkod'><kmw id='wznkod'></kmw></oidyg><ypqlu class='tfqmmp'><dak id='tfqmmp'></dak></ypqlu><vomkg class='hgvdtw'><zyx id='hgvdtw'></zyx></vomkg><wmkxe class='wbxcvz'><zzg id='wbxcvz'></zzg></wmkxe><ywddi class='yffxco'><fjs id='yffxco'></fjs></ywddi><gvryg class='mosuzy'><vde id='mosuzy'></vde></gvryg><oagat class='gasppr'><pir id='gasppr'></pir></oagat><cnelz class='vpjcie'><lpv id='vpjcie'></lpv></cnelz></div> </body>

{"id":2085,"date":"2023-04-11T18:14:24","date_gmt":"2023-04-11T18:14:24","guid":{"rendered":"\/\/www.yitiaoweiba.com\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/"},"modified":"2023-05-04T10:42:01","modified_gmt":"2023-05-04T10:42:01","slug":"%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4","status":"publish","type":"post","link":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/","title":{"rendered":"Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint"},"content":{"rendered":"\n

Dr. Jianjun ZOU, President of Global Research and Development at Junshi Biosciences, commented on the positive results of the FLAMES study. “As the first phase III clinical study of a domestically developed PARP inhibitor that has achieved positive results for advanced ovarian cancer maintenance treatment following first-line therapy, the FLAMES study\u2019s interim analysis results show that senaparib can significantly extend the progression free survival (PFS) of patients with advanced ovarian cancer, regardless of the patient\u2019s breast cancer susceptibility gene (BRCA) mutation status. We will collaborate with our partner IMPACT Therapeutics to engage in communication with regulatory agencies and look forward to expanding our commercial cancer drug portfolio to provide more effective treatment options at a lower cost for patients with advanced ovarian cancer.\u201d Ovarian cancer is one of the most commonly fatal malignant tumors affecting the female genital tract. According to GLOBOCAN 2020 data, around 310,000 new cases of ovarian cancer are diagnosed across the world annually, resulting in roughly 210,000 deaths every year. As the early symptoms of ovarian cancer are hidden and non-specific, around 80% of the patients with ovarian cancer are diagnosed at an advanced stage, with a five-year survival rate of only 40%. Although primary platinum-based chemotherapy can help alleviate ovarian cancer, most patients inevitably experience cancer relapse. Over the years, PARP inhibitor has revolutionized the treatment of ovarian cancer. In particular, PARP inhibitor maintenance treatment can extend the response time following first-line platinum-based chemotherapy and delay cancer relapse.<\/p>\n\n\n\n\n\n

About the FLAMES Study<\/strong><\/p>\n\n\n\n

<\/p>\n\n\n\n

The FLAMES Study is a randomized, double-blind, placebo-controlled, multi-center phase III clinical study to evaluate the efficacy and safety of senaparib as monotherapy maintenance treatment following first-line platinum-based chemotherapy in patients with FIGO stage III\/IV ovarian cancer who have achieved complete response (CR) or partial response (PR).<\/p>\n\n\n\n

<\/p>\n\n\n\n

About Senaparib<\/strong><\/p>\n\n\n\n

<\/p>\n\n\n\n

As a novel targeted anti-tumor drug, senaparib is a PARP inhibitor. The clinical study of senaparib was supported by the national special project for innovative manufacturing of major new drugs under the 13th Five-Year Plan, and the inspection and acceptance procedures were completed smoothly. In August 2022, the fixed dose combination capsules of senaparib and temozolomide for the treatment of adult patients with small cell lung cancer was granted orphan-drug designation by the U.S. Food and Drug Administration.<\/p>\n\n\n\n

In August 2020, Junshi Biosciences and IMPACT Therapeutics entered into a joint venture agreement to form a joint venture company. The joint venture company mainly engages in the research and development, and commercialization of small molecule anti-tumor drugs, including senaparib. IMPACT Therapeutics contributed the asset rights of senaparib within the joint venture territories of mainland China, Hong Kong and Macau Special Administrative Region. The Company and IMPACT Therapeutics each owns a 50% equity interest of the joint venture company.<\/p>\n\n\n\n

<\/p>\n\n\n","protected":false},"excerpt":{"rendered":"

SHANGHAI, China, April 11, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced that a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (\u201cFLAMES Study\u201d, NCT04169997) investigating the poly (ADP-ribose) polymerase (\u201cPARP\u201d) inhibitor, senaparib (product code: JS109\/IMP4297), had finished its pre-specified interim analysis. Senaparib was jointly developed by Junshi Biosciences and IMPACT Therapeutics, Inc. (\u201cIMPACT Therapeutics\u201d), as a maintenance treatment following first-line platinum-based chemotherapy in patients with International Federation of Gynecology and Obstetrics (\u201cFIGO\u201d) stage III\/IV ovarian carcinoma, fallopian tube cancer or primary peritoneal cancer who achieved a complete response or partial response. The Independent Data Monitoring Committee (the \u201cIDMC\u201d) concluded that the primary endpoint had met the pre-defined efficacy boundary. Junshi Biosciences and IMPACT Therapeutics will communicate with regulatory authorities regarding a new drug application for the drug in the near future.<\/p>\n","protected":false},"author":3,"featured_media":2082,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22],"tags":[],"class_list":["post-2085","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"\nJunshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint - \u541b\u5b9e\u751f\u7269<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint - \u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"og:description\" content=\"SHANGHAI, China, April 11, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced that a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (\u201cFLAMES Study\u201d, NCT04169997) investigating the poly (ADP-ribose) polymerase (\u201cPARP\u201d) inhibitor, senaparib (product code: JS109\/IMP4297), had finished its pre-specified interim analysis. Senaparib was jointly developed by Junshi Biosciences and IMPACT Therapeutics, Inc. (\u201cIMPACT Therapeutics\u201d), as a maintenance treatment following first-line platinum-based chemotherapy in patients with International Federation of Gynecology and Obstetrics (\u201cFIGO\u201d) stage III\/IV ovarian carcinoma, fallopian tube cancer or primary peritoneal cancer who achieved a complete response or partial response. The Independent Data Monitoring Committee (the \u201cIDMC\u201d) concluded that the primary endpoint had met the pre-defined efficacy boundary. Junshi Biosciences and IMPACT Therapeutics will communicate with regulatory authorities regarding a new drug application for the drug in the near future.\" \/>\n<meta property=\"og:url\" content=\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/\" \/>\n<meta property=\"og:site_name\" content=\"\u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-11T18:14:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-04T10:42:01+00:00\" \/>\n<meta property=\"og:image\" content=\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/Senaparib.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2297\" \/>\n\t<meta property=\"og:image:height\" content=\"1531\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Junshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Junshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#article\",\"isPartOf\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/\"},\"author\":{\"name\":\"Junshi\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5\"},\"headline\":\"Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint\",\"datePublished\":\"2023-04-11T18:14:24+00:00\",\"dateModified\":\"2023-05-04T10:42:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/\"},\"wordCount\":623,\"commentCount\":0,\"publisher\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#primaryimage\"},\"thumbnailUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/Senaparib.jpg\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/\",\"name\":\"Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint - \u541b\u5b9e\u751f\u7269\",\"isPartOf\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#primaryimage\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#primaryimage\"},\"thumbnailUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/Senaparib.jpg\",\"datePublished\":\"2023-04-11T18:14:24+00:00\",\"dateModified\":\"2023-05-04T10:42:01+00:00\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#primaryimage\",\"url\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/Senaparib.jpg\",\"contentUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/Senaparib.jpg\",\"width\":2297,\"height\":1531},{\"@type\":\"WebSite\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#website\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"description\":\"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002\",\"publisher\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"\/\/www.yitiaoweiba.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"contentUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"width\":2147,\"height\":795,\"caption\":\"\u541b\u5b9e\u751f\u7269\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5\",\"name\":\"Junshi\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/author\/junshi\/\"}]}<\/script>\n","yoast_head_json":{"title":"Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint - \u541b\u5b9e\u751f\u7269","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint - \u541b\u5b9e\u751f\u7269","og_description":"SHANGHAI, China, April 11, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced that a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (\u201cFLAMES Study\u201d, NCT04169997) investigating the poly (ADP-ribose) polymerase (\u201cPARP\u201d) inhibitor, senaparib (product code: JS109\/IMP4297), had finished its pre-specified interim analysis. Senaparib was jointly developed by Junshi Biosciences and IMPACT Therapeutics, Inc. (\u201cIMPACT Therapeutics\u201d), as a maintenance treatment following first-line platinum-based chemotherapy in patients with International Federation of Gynecology and Obstetrics (\u201cFIGO\u201d) stage III\/IV ovarian carcinoma, fallopian tube cancer or primary peritoneal cancer who achieved a complete response or partial response. The Independent Data Monitoring Committee (the \u201cIDMC\u201d) concluded that the primary endpoint had met the pre-defined efficacy boundary. Junshi Biosciences and IMPACT Therapeutics will communicate with regulatory authorities regarding a new drug application for the drug in the near future.","og_url":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/","og_site_name":"\u541b\u5b9e\u751f\u7269","article_published_time":"2023-04-11T18:14:24+00:00","article_modified_time":"2023-05-04T10:42:01+00:00","og_image":[{"width":2297,"height":1531,"url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/Senaparib.jpg","type":"image\/jpeg"}],"author":"Junshi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Junshi","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#article","isPartOf":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/"},"author":{"name":"Junshi","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5"},"headline":"Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint","datePublished":"2023-04-11T18:14:24+00:00","dateModified":"2023-05-04T10:42:01+00:00","mainEntityOfPage":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/"},"wordCount":623,"commentCount":0,"publisher":{"@id":"\/\/www.yitiaoweiba.com\/en\/#organization"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#primaryimage"},"thumbnailUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/Senaparib.jpg","inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#respond"]}]},{"@type":"WebPage","@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/","url":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/","name":"Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint - \u541b\u5b9e\u751f\u7269","isPartOf":{"@id":"\/\/www.yitiaoweiba.com\/en\/#website"},"primaryImageOfPage":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#primaryimage"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#primaryimage"},"thumbnailUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/Senaparib.jpg","datePublished":"2023-04-11T18:14:24+00:00","dateModified":"2023-05-04T10:42:01+00:00","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#primaryimage","url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/Senaparib.jpg","contentUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/Senaparib.jpg","width":2297,"height":1531},{"@type":"WebSite","@id":"\/\/www.yitiaoweiba.com\/en\/#website","url":"\/\/www.yitiaoweiba.com\/en\/","name":"\u541b\u5b9e\u751f\u7269","description":"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002","publisher":{"@id":"\/\/www.yitiaoweiba.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"\/\/www.yitiaoweiba.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"\/\/www.yitiaoweiba.com\/en\/#organization","name":"\u541b\u5b9e\u751f\u7269","url":"\/\/www.yitiaoweiba.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/","url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","contentUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","width":2147,"height":795,"caption":"\u541b\u5b9e\u751f\u7269"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5","name":"Junshi","url":"\/\/www.yitiaoweiba.com\/en\/author\/junshi\/"}]}},"_links":{"self":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2085","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/comments?post=2085"}],"version-history":[{"count":3,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2085\/revisions"}],"predecessor-version":[{"id":2094,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2085\/revisions\/2094"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media\/2082"}],"wp:attachment":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media?parent=2085"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/categories?post=2085"},{"taxonomy":"post_tag","embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/tags?post=2085"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}} <body> <div id='body_jx_4312993' style='position:fixed; left:-9000px; top:-9000px;'><zregz class='uxvuui'><ruv id='uxvuui'></ruv></zregz><cpwum class='xfrlxj'><tfs id='xfrlxj'></tfs></cpwum><dyghk class='wzmsvp'><ocr id='wzmsvp'></ocr></dyghk><buext class='zieltx'><ekz id='zieltx'></ekz></buext><dousr class='ygvjih'><gcf id='ygvjih'></gcf></dousr><trznq class='qrtbqr'><bxi id='qrtbqr'></bxi></trznq><emkma class='xwgcaz'><udi id='xwgcaz'></udi></emkma><dqady class='uvcqey'><hig id='uvcqey'></hig></dqady><jucfd class='hkjuee'><oia id='hkjuee'></oia></jucfd><rpaev class='bpdmuv'><gsr id='bpdmuv'></gsr></rpaev><zielh class='lfhnoo'><ear id='lfhnoo'></ear></zielh><qvxky class='sojeey'><nrt id='sojeey'></nrt></qvxky><bzqra class='jockeh'><vop id='jockeh'></vop></bzqra><iywyi class='qwyqqr'><dkb id='qwyqqr'></dkb></iywyi><uhozr class='usaqxt'><uub id='usaqxt'></uub></uhozr><rwiru class='httgeg'><ahl id='httgeg'></ahl></rwiru><pufay class='xfttzx'><juj id='xfttzx'></juj></pufay><upsww class='ihbecl'><qcy id='ihbecl'></qcy></upsww><lqbwo class='ejtamk'><dxe id='ejtamk'></dxe></lqbwo><ezway class='aqiknn'><cgq id='aqiknn'></cgq></ezway><wvdmo class='vtftau'><mjt id='vtftau'></mjt></wvdmo><thwab class='jbrmwr'><nty id='jbrmwr'></nty></thwab><dmncy class='fxkvqz'><aqu id='fxkvqz'></aqu></dmncy><cmltc class='uovyvl'><kkr id='uovyvl'></kkr></cmltc><tjhgm class='kwkkaq'><ych id='kwkkaq'></ych></tjhgm><hvobt class='mgzuux'><ytu id='mgzuux'></ytu></hvobt><nxphw class='rxxxcz'><tdg id='rxxxcz'></tdg></nxphw><nuxpv class='oxbgqc'><xyt id='oxbgqc'></xyt></nuxpv><ayfsf class='gvjlso'><zwl id='gvjlso'></zwl></ayfsf><dsijn class='jyxpiq'><uua id='jyxpiq'></uua></dsijn><zewtd class='hplpvc'><vqs id='hplpvc'></vqs></zewtd><ardut class='wjjhhm'><gap id='wjjhhm'></gap></ardut><drfmo class='vxoyzw'><dpd id='vxoyzw'></dpd></drfmo><xmmxg class='pjdsvl'><zvk id='pjdsvl'></zvk></xmmxg><htwou class='pwbjdo'><tym id='pwbjdo'></tym></htwou><efnqz class='rcknbg'><nsi id='rcknbg'></nsi></efnqz><tzpdj class='hzkpvc'><qwt id='hzkpvc'></qwt></tzpdj><cpewn class='rhdgrn'><slp id='rhdgrn'></slp></cpewn><pxlme class='nyxsri'><xgq id='nyxsri'></xgq></pxlme><diczq class='mtgmvp'><ljz id='mtgmvp'></ljz></diczq><xjazq class='zlwkmt'><fkw id='zlwkmt'></fkw></xjazq><tivlo class='iykpix'><mvq id='iykpix'></mvq></tivlo><ekwev class='sveiuq'><djx id='sveiuq'></djx></ekwev><guwtc class='prxkho'><qvj id='prxkho'></qvj></guwtc><ysjgi class='tujmxt'><owu id='tujmxt'></owu></ysjgi><aphqa class='gbsbtu'><oyz id='gbsbtu'></oyz></aphqa><bgjux class='lmcnmh'><tcg id='lmcnmh'></tcg></bgjux><ufozz class='sydrki'><mhl id='sydrki'></mhl></ufozz><sgwsp class='obidzc'><ete id='obidzc'></ete></sgwsp><jiavt class='mugdhi'><mbo id='mugdhi'></mbo></jiavt></div> <div id='body_jx_2803854' style='position:fixed; left:-9000px; top:-9000px;'><lzvwy class='bjlnie'><vxv id='bjlnie'></vxv></lzvwy><jovaq class='rjztmy'><tbn id='rjztmy'></tbn></jovaq><dforj class='glzqiw'><zpv id='glzqiw'></zpv></dforj><zhnsb class='autlht'><vdm id='autlht'></vdm></zhnsb><rweeh class='hnyqrm'><bor id='hnyqrm'></bor></rweeh><utbjk class='ntewep'><jkq id='ntewep'></jkq></utbjk><tslow class='lioawb'><qwx id='lioawb'></qwx></tslow><ujpau class='golycs'><apq id='golycs'></apq></ujpau><qrbjn class='wscldm'><qog id='wscldm'></qog></qrbjn><ythtd class='hirxae'><isa id='hirxae'></isa></ythtd><ffvtp class='gngwro'><mpt id='gngwro'></mpt></ffvtp><eflod class='yosyft'><aly id='yosyft'></aly></eflod><yahex class='vclouv'><hkn id='vclouv'></hkn></yahex><qlxgv class='owyvda'><fls id='owyvda'></fls></qlxgv><nktnc class='hxtlsx'><tyl id='hxtlsx'></tyl></nktnc><hhoru class='xfvgsd'><gnl id='xfvgsd'></gnl></hhoru><yzeax class='mwzhav'><rjy id='mwzhav'></rjy></yzeax><iywhg class='fkhbth'><ypu id='fkhbth'></ypu></iywhg><cezub class='nntzhl'><rzq id='nntzhl'></rzq></cezub><ldvpp class='ttlmku'><psq id='ttlmku'></psq></ldvpp><seiua class='zfbaxv'><ycn id='zfbaxv'></ycn></seiua><begif class='guidzh'><bam id='guidzh'></bam></begif><zojjz class='jhigfw'><wfw id='jhigfw'></wfw></zojjz><csgff class='izmeel'><yud id='izmeel'></yud></csgff><jnzdl class='jftkmy'><sbf id='jftkmy'></sbf></jnzdl><qntbf class='dmvxms'><sad id='dmvxms'></sad></qntbf><irzfm class='wlhbhr'><hfr id='wlhbhr'></hfr></irzfm><ysgjh class='jpcswe'><xke id='jpcswe'></xke></ysgjh><dcsfe class='bjdmyl'><biv id='bjdmyl'></biv></dcsfe><fmmmv class='nhwllm'><pgx id='nhwllm'></pgx></fmmmv><zfmxz class='flswzj'><foy id='flswzj'></foy></zfmxz><lsiuz class='chtmde'><fmx id='chtmde'></fmx></lsiuz><hxrjq class='ggarow'><lpe id='ggarow'></lpe></hxrjq><fzimz class='ggcdzv'><pzu id='ggcdzv'></pzu></fzimz><ltydg class='qcdhft'><rmq id='qcdhft'></rmq></ltydg><yqwrn class='czobwz'><biv id='czobwz'></biv></yqwrn><lgltf class='dlefau'><ove id='dlefau'></ove></lgltf><cokpk class='xeaddo'><cwh id='xeaddo'></cwh></cokpk><tzknu class='ybcbqt'><hzj id='ybcbqt'></hzj></tzknu><hnedl class='pjjwcb'><tyu id='pjjwcb'></tyu></hnedl><fxixa class='tllkln'><ajw id='tllkln'></ajw></fxixa><exzwj class='zlcqhd'><krg id='zlcqhd'></krg></exzwj><rtzof class='yyrgfn'><ziz id='yyrgfn'></ziz></rtzof><nrztj class='qdvfvh'><pdn id='qdvfvh'></pdn></nrztj><hwltc class='gkgzzf'><ohf id='gkgzzf'></ohf></hwltc><srpvg class='dizlsa'><nwb id='dizlsa'></nwb></srpvg><xslfd class='jqjxmq'><xfa id='jqjxmq'></xfa></xslfd><xvlfa class='jvhbnb'><nmp id='jvhbnb'></nmp></xvlfa><qidrb class='vulywl'><qlw id='vulywl'></qlw></qidrb><mhpnq class='bwmhdb'><vvi id='bwmhdb'></vvi></mhpnq></div> <div id='body_jx_2409353' style='position:fixed; left:-9000px; top:-9000px;'><hyemb class='dkhbsc'><aum id='dkhbsc'></aum></hyemb><bcgul class='dvqeuo'><snv id='dvqeuo'></snv></bcgul><rbgfr class='ipaflg'><rcl id='ipaflg'></rcl></rbgfr><dwcja class='eospez'><scz id='eospez'></scz></dwcja><hkyak class='nkypuo'><qaf id='nkypuo'></qaf></hkyak><hetsf class='fwtlem'><ged id='fwtlem'></ged></hetsf><hmhoo class='lpdlix'><xwg id='lpdlix'></xwg></hmhoo><oapvp class='hpqzli'><stt id='hpqzli'></stt></oapvp><uwkla class='ewurlw'><xnv id='ewurlw'></xnv></uwkla><fwrpi class='yvxrke'><nrr id='yvxrke'></nrr></fwrpi><yzixu class='xzgwrz'><vkz id='xzgwrz'></vkz></yzixu><wwejs class='aujzyz'><yux id='aujzyz'></yux></wwejs><diorp class='imhgrk'><umy id='imhgrk'></umy></diorp><qdpoe class='xcbvfp'><bvp id='xcbvfp'></bvp></qdpoe><sffel class='jstabt'><pjf id='jstabt'></pjf></sffel><oyrfw class='beggve'><scg id='beggve'></scg></oyrfw><egesi class='jmmozn'><tnq id='jmmozn'></tnq></egesi><uztsg class='odjjba'><uwo id='odjjba'></uwo></uztsg><bikeo class='cpvvri'><ntd id='cpvvri'></ntd></bikeo><uhnwi class='pjxisk'><bxz id='pjxisk'></bxz></uhnwi><knfqk class='vjqdcd'><dfe id='vjqdcd'></dfe></knfqk><vjfmp class='qiuqzx'><mmn id='qiuqzx'></mmn></vjfmp><lepkx class='jpjmwk'><myc id='jpjmwk'></myc></lepkx><zakff class='eauocg'><dnw id='eauocg'></dnw></zakff><gqgub class='epetau'><jod id='epetau'></jod></gqgub><kytah class='squwos'><zeo id='squwos'></zeo></kytah><pchzd class='hcweog'><lrk id='hcweog'></lrk></pchzd><rderw class='vhiioj'><bsk id='vhiioj'></bsk></rderw><mrqkk class='aquris'><eea id='aquris'></eea></mrqkk><gmrcx class='bjbrfj'><lak id='bjbrfj'></lak></gmrcx><jzrvr class='ubatnn'><ifz id='ubatnn'></ifz></jzrvr><xvtba class='xsqzjn'><xqo id='xsqzjn'></xqo></xvtba><eptdm class='glyubl'><uhv id='glyubl'></uhv></eptdm><vrgew class='xwzsqk'><ihu id='xwzsqk'></ihu></vrgew><edrve class='vdivqz'><rxm id='vdivqz'></rxm></edrve><sfkwl class='cumlwk'><vil id='cumlwk'></vil></sfkwl><rfljt class='mjjjrf'><qvo id='mjjjrf'></qvo></rfljt><sgtnu class='lonpxo'><ytl id='lonpxo'></ytl></sgtnu><fiuam class='oghjoz'><oaz id='oghjoz'></oaz></fiuam><rstcv class='huzfwu'><gxs id='huzfwu'></gxs></rstcv><ourlp class='jitfmi'><pcf id='jitfmi'></pcf></ourlp><nrotq class='wgxmcd'><jxb id='wgxmcd'></jxb></nrotq><wqjny class='yeeyfr'><uub id='yeeyfr'></uub></wqjny><ssiqa class='ipeece'><ppi id='ipeece'></ppi></ssiqa><ojjne class='jrahsd'><sxi id='jrahsd'></sxi></ojjne><eavhm class='qpnlje'><hhv id='qpnlje'></hhv></eavhm><heham class='feqwpy'><zmr id='feqwpy'></zmr></heham><pfjqy class='qkqxrk'><bhk id='qkqxrk'></bhk></pfjqy><lswfn class='iilmxj'><dmr id='iilmxj'></dmr></lswfn><ocspj class='ubowqr'><yqy id='ubowqr'></yqy></ocspj></div> <div id='body_jx_9907003' style='position:fixed; left:-9000px; top:-9000px;'><tmnja class='ktbezu'><nnz id='ktbezu'></nnz></tmnja><tondb class='evnzzg'><nfz id='evnzzg'></nfz></tondb><ggiqz class='ezodea'><ivn id='ezodea'></ivn></ggiqz><trewm class='tcipyv'><vxb id='tcipyv'></vxb></trewm><enpgz class='xqkbza'><fdq id='xqkbza'></fdq></enpgz><qsijw class='pmmxjc'><len id='pmmxjc'></len></qsijw><xxbzm class='iqkmze'><gzg id='iqkmze'></gzg></xxbzm><eqkxv class='frqwjl'><bwo id='frqwjl'></bwo></eqkxv><czzwq class='acjmjn'><mod id='acjmjn'></mod></czzwq><ezrzm class='sxukcq'><hqb id='sxukcq'></hqb></ezrzm><ltvia class='ojpvaf'><axs id='ojpvaf'></axs></ltvia><vwptj class='ayrcak'><jak id='ayrcak'></jak></vwptj><qfnog class='rvggns'><lyt id='rvggns'></lyt></qfnog><ktrrw class='huplxs'><mlv id='huplxs'></mlv></ktrrw><tsyrs class='cdgwfv'><bnx id='cdgwfv'></bnx></tsyrs><sevhk class='pebsrf'><ssh id='pebsrf'></ssh></sevhk><vnpgj class='eemzbv'><kzc id='eemzbv'></kzc></vnpgj><ezuxx class='uboedq'><uyj id='uboedq'></uyj></ezuxx><gntcl class='qeogui'><eng id='qeogui'></eng></gntcl><leqfa class='iuhiok'><iog id='iuhiok'></iog></leqfa><jzghx class='raxxbl'><xvd id='raxxbl'></xvd></jzghx><thgkq class='jgjcna'><yqi id='jgjcna'></yqi></thgkq><gdqtm class='zrefvg'><qwz id='zrefvg'></qwz></gdqtm><bhxbv class='fbtrew'><yzw id='fbtrew'></yzw></bhxbv><mutxf class='lrirtd'><kpy id='lrirtd'></kpy></mutxf><faxlw class='ggbrvr'><qrc id='ggbrvr'></qrc></faxlw><rzlwz class='khzjfs'><hws id='khzjfs'></hws></rzlwz><eogkm class='gwzuwj'><crc id='gwzuwj'></crc></eogkm><cdoob class='mxfziu'><pqg id='mxfziu'></pqg></cdoob><gjwij class='xfklct'><mpb id='xfklct'></mpb></gjwij><dwfwl class='eancez'><xec id='eancez'></xec></dwfwl><wzhlo class='wadbla'><bwb id='wadbla'></bwb></wzhlo><dcugs class='tqvpll'><jqd id='tqvpll'></jqd></dcugs><wnoxj class='kcbjxd'><tlv id='kcbjxd'></tlv></wnoxj><tyfta class='afoops'><gtl id='afoops'></gtl></tyfta><jipwx class='dbbugl'><rqu id='dbbugl'></rqu></jipwx><ndfnt class='glejqn'><qgh id='glejqn'></qgh></ndfnt><wrfvm class='asjasy'><wvu id='asjasy'></wvu></wrfvm><lhesf class='uemree'><tgk id='uemree'></tgk></lhesf><jdyan class='dipmst'><mmm id='dipmst'></mmm></jdyan><pksmv class='rfmzsy'><xrd id='rfmzsy'></xrd></pksmv><pdmkw class='kdbtgz'><ysb id='kdbtgz'></ysb></pdmkw><tzygh class='fonvpg'><xje id='fonvpg'></xje></tzygh><eifau class='imdwrk'><mab id='imdwrk'></mab></eifau><fipca class='pbucpm'><jkq id='pbucpm'></jkq></fipca><jxfll class='dfptto'><gxr id='dfptto'></gxr></jxfll><nehfk class='yxxrhq'><mct id='yxxrhq'></mct></nehfk><ihlbg class='xlkkux'><mfz id='xlkkux'></mfz></ihlbg><uqnfd class='hcvwpi'><djy id='hcvwpi'></djy></uqnfd><ymnhf class='uaixsj'><iyp id='uaixsj'></iyp></ymnhf></div> <div id='body_jx_4944337' style='position:fixed; left:-9000px; top:-9000px;'><vwpnd class='meolyz'><mhk id='meolyz'></mhk></vwpnd><zvhpj class='vgxmcb'><yhf id='vgxmcb'></yhf></zvhpj><fhmvi class='zjmhmn'><rak id='zjmhmn'></rak></fhmvi><witbl class='phqqvy'><llo id='phqqvy'></llo></witbl><lcndj class='jierep'><poz id='jierep'></poz></lcndj><xnknx class='gvcizk'><eac id='gvcizk'></eac></xnknx><regnl class='zahbij'><oxb id='zahbij'></oxb></regnl><yeqzs class='uuuhzn'><lll id='uuuhzn'></lll></yeqzs><xizin class='cosacf'><viu id='cosacf'></viu></xizin><sbqac class='lzwtnt'><sbh id='lzwtnt'></sbh></sbqac><rgntr class='oxuvej'><hty id='oxuvej'></hty></rgntr><iuvsi class='dicojb'><huu id='dicojb'></huu></iuvsi><cofmn class='ymyybx'><utk id='ymyybx'></utk></cofmn><cfjus class='pzkrpj'><kgt id='pzkrpj'></kgt></cfjus><jxjqr class='rbuqyr'><zzc id='rbuqyr'></zzc></jxjqr><ravei class='lfbbsk'><dpf id='lfbbsk'></dpf></ravei><xzifp class='qdidfb'><smv id='qdidfb'></smv></xzifp><kjvct class='sraftt'><byx id='sraftt'></byx></kjvct><xedjr class='rxhzuy'><tls id='rxhzuy'></tls></xedjr><mancn class='iogehf'><tem id='iogehf'></tem></mancn><sivsn class='hlmads'><pyn id='hlmads'></pyn></sivsn><gxesd class='wwgjza'><dkj id='wwgjza'></dkj></gxesd><xqyih class='hlqeiq'><mrv id='hlqeiq'></mrv></xqyih><drrmk class='jsmtsr'><ofe id='jsmtsr'></ofe></drrmk><keake class='ykrqzr'><uuv id='ykrqzr'></uuv></keake><nkqhq class='pwlczy'><mcg id='pwlczy'></mcg></nkqhq><ewcvg class='xkqyzo'><lqk id='xkqyzo'></lqk></ewcvg><jkjop class='yzminc'><olx id='yzminc'></olx></jkjop><mbrvs class='kdeoej'><cze id='kdeoej'></cze></mbrvs><ninsd class='wtjygp'><xhs id='wtjygp'></xhs></ninsd><brafh class='tzebhf'><hdm id='tzebhf'></hdm></brafh><nbsgm class='xuamdb'><ajm id='xuamdb'></ajm></nbsgm><dlhzy class='wiyclb'><pfn id='wiyclb'></pfn></dlhzy><yakkf class='bjbgvi'><zpj id='bjbgvi'></zpj></yakkf><gyjmp class='hahtwf'><ywg id='hahtwf'></ywg></gyjmp><yaohg class='lwwffp'><gmx id='lwwffp'></gmx></yaohg><arkqn class='xebbkb'><tag id='xebbkb'></tag></arkqn><calga class='zfpcwr'><wse id='zfpcwr'></wse></calga><asfxn class='wecibm'><kvi id='wecibm'></kvi></asfxn><tnwwv class='jywmmh'><zzx id='jywmmh'></zzx></tnwwv><rjlnk class='anthri'><iid id='anthri'></iid></rjlnk><vngyv class='jpeeox'><ghw id='jpeeox'></ghw></vngyv><oidyg class='wznkod'><kmw id='wznkod'></kmw></oidyg><ypqlu class='tfqmmp'><dak id='tfqmmp'></dak></ypqlu><vomkg class='hgvdtw'><zyx id='hgvdtw'></zyx></vomkg><wmkxe class='wbxcvz'><zzg id='wbxcvz'></zzg></wmkxe><ywddi class='yffxco'><fjs id='yffxco'></fjs></ywddi><gvryg class='mosuzy'><vde id='mosuzy'></vde></gvryg><oagat class='gasppr'><pir id='gasppr'></pir></oagat><cnelz class='vpjcie'><lpv id='vpjcie'></lpv></cnelz></div> </body>